4521
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Kaken Pharmaceutical Co., Ltd. is a pharmaceutical company operating in the pharmaceutical and real estate sectors. The group manufactures and sells pharmaceuticals, medical devices, and agricultural chemicals. Its business activities are conducted through subsidiaries including Kaken Pharma Co., Ltd., Arsum Co., Ltd., KAKEN INVESTMENTS INC., and Ardi Co. The real estate segment focuses on property leasing. The company serves markets requiring its specific pharmaceutical and agricultural products, with operations structured around these two primary business lines.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage kaken.co.jp
Sector Healthcare IR page kaken.co.jp
Tags
pharmaceuticals, medical devices, agricultural chemicals, real estate leasing, Kaken Pharma Co. Ltd., Arsum Co. Ltd., KAKEN INVESTMENTS INC., Ardi Co.
Press page —

Metrics

Valuation  
Market cap ¥ 168.614B
Market cap (USD) $ 1.054B
P/E 15.80
PEG —
P/BV 1.10
P/S 1.95
P/OCF 15.09
P/FCF 32.00
Dividend yield 5.0%
Turnover / mcap —
Returns  
ROE 1.4%
ROI 1.4%
ROIC -0.55%
Profit margin 2.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -26.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 76.871B 94.035B 72.044B 72.984B 76.034B 74.979B 89.232B 94.165B 98.43B 101.479B 109.73B 93.889B 88.946B 87.054B
Net profit 2.144B 13.945B 8.025B 5.44B 9.549B 13.405B 19.37B 17.775B 19.043B 22.017B 21.143B 12.122B 9.735B 8.991B
Free cash flow -16.502B 25.388B 410M 7.047B 10.079B 12.094B 25.266B 19.001B 19.815B 12.973B 23.85B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 4.141K 4.489K 3.464K 3.692K 3.89K 4.338K 5.04K 5.026K 6.27K 6.295K 6.792K 6.952K 3.262K 3.451K
Price performance 12m -0.08 0.3 -0.06 -0.05 -0.1 -0.14 0 -0.2 -0 -0.07 -0.02 1.13 -0.05 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 28.2B 33.3B 30.3B 21.8B 20.5B 40.2B 38.2B 47.1B 41.9B 38.3B
↳ YoY growth -5.5% +18.0% -8.9% -28.1% -5.7% +95.8% -5.2% +23.4% -11.0% -8.5%
↳ 5y CAGR -7.2% +7.3% +2.8% +9.2% +14.0% +13.3%
Borrowings, current (JPY) 3.88B 3.88B 3.88B 3.85B 3.85B 3.85B 3.85B 3.85B 3.85B 3.85B
Cash and deposits (JPY) 33.9B 45.1B 47B 59.7B 63.7B 61B 59.6B 50.6B 54.1B 44.7B
Intangible assets (JPY) 372M 552M 551M 414M 625M 8.24B 6.74B 7.46B 19.3B 24.3B
Net debt (borrowings + leases - cash) (JPY) -30B -41.2B -43.1B -55.9B -59.9B -57.2B -55.7B -46.8B -50.2B -40.9B
Cash flow detail
Operating cash flow (JPY) 15.3B 21.7B 21.1B 27.5B 14.4B 13.3B 9.25B 2.58B 29.8B -11.1B
Purchases of property, plant and equipment (JPY) -2.17B -1.69B -1.91B -2.16B -1.97B -2.99B -1.99B -1.86B -4.14B -3B
Purchases of intangible assets (JPY) -188M -199M -220M -43M -313M -271M -219M -306M -254M -2.43B
Change in receivables (cash effect) (JPY) 1.64B -5.08B 2.98B 8.54B 1.25B 392M 972M -4.56B 3.58B 1.84B
Change in inventories (cash effect) (JPY) -1.99B -155M 2.93B 1.45B -2.92B 241M -583M -1.6B -1.08B -59M
Change in payables (cash effect) (JPY) -1.09B 2.29B -1.19B -3.58B -112M -2.63B 280M 880M 1.1B -769M
Dividends paid (cash effect) (JPY) -6.29B -6.09B -6B -5.9B -5.81B -5.71B -5.65B -5.66B -7.2B -6.5B
Share buybacks (cash effect) (JPY) — — — — — — — -2M -5.94B -2.34B
Interest paid (cash effect) (JPY) -21M -16M -17M -17M -17M -17M -17M -17M -28M -45M
Income taxes paid (cash effect) (JPY) -13.8B -7.08B -9.07B -7.81B -5.52B -4.43B -4.41B -3.79B -836M -10.7B
Operating cash flow before change in receivables (JPY) 13.7B 26.8B 18.2B 18.9B 13.1B 12.9B 8.28B 7.14B 26.2B -12.9B
Free cash flow (OCF - PPE - intangibles) (JPY) 13B 19.8B 19B 25.3B 12.1B 10.1B 7.05B 410M 25.4B -16.5B
Income detail
Research and development expense (JPY) 6.45B 8.15B 10.3B 6.42B 6.74B 8.42B 15.8B 12.5B 18.7B 20.6B
↳ 5y CAGR +2.7% +5.5% +14.1% +4.1% +23.9% +25.0%
Total comprehensive income (JPY) 22.6B 20.8B 16.8B 17.5B 16.5B 9.56B 5.48B 11.7B 14.2B 3.81B
Comprehensive income to owners (JPY) 22.6B 20.8B 16.8B 17.5B 16.5B 9.56B 5.48B 11.7B 14.2B 3.81B
Reported Jun 29, 2017 Jun 28, 2018 Jun 27, 2019 Jun 26, 2020 Jun 29, 2021 Jun 29, 2022 Jun 29, 2023 Jun 26, 2025 Jun 26, 2025 Jun 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Kaken Pharmaceutical Co., Ltd. (ticker 4521), listed in Japan.

ETFs Holding Kaken Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
DXIV 0.02% 1,900 $ 45.629K Nov 12, 2026
DISV 0.01% 21,800 $ 523.527K Nov 12, 2026
DFIS 0.00% 11,000 $ 264.165K Nov 12, 2026
DFAX 0.00% 20,500 $ 492.308K Nov 12, 2026
DFSI 0.00% 500 $ 12.008K Nov 12, 2026
AVDS 0.00% 100 $ 2,395.25 Nov 16, 2026